Tyra Biosciences (TYRA) Stock: Buy, Sell, or Hold?
TYRA - Tyra Biosciences, Inc. Common Stock
$20.58
-0.02 (-0.10%)
▼
5d:
+8.09%
30d:
-11.41%
90d:
-32.81%
BUY
HIGH Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 04, 2026
12d
Get Alerted When TYRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TYRA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: TYRA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: TYRA is currently trading at $20.58, which is considered fair relative to its 30-day fair value range of $19.34 to $23.92.
Technical Outlook: Technically, TYRA is in a strong downtrend. The price is approaching resistance at $20.99. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TYRA scores 83/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (20th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $47.45 (+130.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TYRA is in a strong downtrend. The price is approaching resistance at $20.99. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TYRA scores 83/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (20th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $47.45 (+130.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$19.34 -
$23.92
Company Quality Score
57/100
(HOLD)
Options IV Signal
20th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 20th percentile)
- BULLISH: Strong technical setup (83/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 130.4% below Wall St target ($47.45)
- BULLISH: Bottoming setup score 83/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$19.34 -
$23.92
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$2.10
(10.2%)
Support & Resistance Levels
Support Level
$18.25
Resistance Level
$20.99
Current Trend
Strong Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.44
Wall Street Target
$47.45
(+130.4%)
Share & Embed Analysis
Last updated: October 22, 2026 8:51 AM ET
Data refreshes hourly during market hours. Next update: 9:51 AM
Data refreshes hourly during market hours. Next update: 9:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TYRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 71 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 69 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 58 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 64 BUY |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
15 analysts |
$108 | 68 BUY |
